Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

chronic kidney disease, or severe obesity should be considered for RSV vaccination in their 50s. Michael Melgar, a CDC vaccines researcher, said around 30% of U.S. adults aged 50 to 59 would qualify.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 ... virus-related lower respiratory tract disease (RSV-LRTD) in adults aged 60 and older ...

"These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research," said Tony Wood, GSK Chief Scientific ...

ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases. "ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59" was ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

THURSDAY, April 17, 2025 (HealthDay News) — A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV ...